Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic

Lancet Oncol. 2022 Feb;23(2):195-197. doi: 10.1016/S1470-2045(21)00708-7.
No abstract available

Publication types

  • Comment

MeSH terms

  • COVID-19*
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6
  • Humans
  • Pandemics
  • SARS-CoV-2

Substances

  • CDK4 protein, human
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6